StreetInsider.com News Articles

Form 4 PALISADE BIO, INC. For: Oct 19 Filed by: Capers Julien E.

Wed, 21 Oct 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20261021/27217396.html

Form 3 PALISADE BIO, INC. For: Oct 19 Filed by: Capers Julien E.

Wed, 21 Oct 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20261021/27217246.html

Oppenheimer Reiterates Outperform Rating on Palisade Bio Inc. (PALI)

Wed, 21 Oct 2026 04:03:13 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $8.00 price target on Palisade Bio Inc. (NASDAQ: PALI).

The analyst comments "PALI presented additional PALI-2108 data at UEG Week, adding to the evidence for its gut-targeted approach in Crohn's disease—where treatment needs to reach the ileum as well as the colon. The headline endoscopic results were previously reported, but new tissue analyses showed reduced PDE4D expression and exploratory signs of tissue remodeling. Interestingly, one previously non-traversable stricture became passable after just 14 days, although reduced inflammation or edema is a more likely explanation than fibrosis reversal given the short time to

Palisade Bio reports Phase 1b data for PALI-2108 at UEG Week 2026

Tue, 20 Oct 2026 08:06:11 -0400

Palisade Bio, Inc. (Nasdaq: PALI) presented clinical and translational data for its investigational drug PALI-2108 at United European Gastroenterology Week 2026, held October 17–20 in Barcelona, Spain, according to a company statement.

In a five-patient Phase 1b open-label cohort of fibrostenotic Crohn's disease, mean endoscopic disease activity as measured by the Simple Endoscopic Score for Crohn's Disease decreased by 47.5% after 14 days of once-daily PALI-2108. Mean fecal calprotectin fell 58.8% from baseline. Two of five patients achieved endoscopic response and two achieved endoscopic remission. Four of the five patients were receiving concomitant biologic therapy. All reported adverse events were mild,

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Tue, 20 Oct 2026 08:05:00 -0400

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon

Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated

Denver, CO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Tue, 20 Oct 2026 08:05:00 -0400

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon

Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Tue, 13 Oct 2026 06:51:33 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $7.00 price target on Palisade Bio Inc. (NASDAQ: PALI).

The analyst commented: "PALI-2108’s 40% endoscopic response gets tissue-level support, risk-mitigating Phase 2 data in broader Crohn’s disease. Palisade Bio presented five posters at the American College of Gastroenterology (ACG) meeting being held October 9-14 in Nashville, TN, including new evidence of reduced inflammatory-cell densities in paired intestinal biopsies from its five-patient Phase 1b fibrostenotic Crohn’s disease (FSCD) cohort. These findings complement previously reported increases in ileal cAMP, a 47.5% reduction in mean Simple Endoscopic Score for Crohn’s Disease (SES-CD) from

Palisade Bio presents Phase 2 data for PALI-2108 at ACG 2026

Mon, 12 Oct 2026 08:05:16 -0400

Palisade Bio, Inc. (Nasdaq: PALI) presented five poster presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville, Tennessee, reporting clinical, pharmacokinetic, pharmacodynamic, and mechanistic data from its Phase 1 studies of PALI-2108, an investigational oral PDE4 inhibitor prodrug being evaluated for ulcerative colitis and Crohn's disease.

In a small open-label ulcerative colitis cohort of five patients treated for seven days, all achieved clinical response and two achieved clinical remission, with a reported 62.8% mean reduction in modified Mayo score. Colonic tissue cAMP increased in four of five patients and PDE4B expression decreased in all five. In a

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

Mon, 12 Oct 2026 08:05:00 -0400

Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development

Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts

Microbiome and transcriptomic analyses support the delivery platform and a potential precision medicine approach

Denver, CO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral therapies for immune-mediated diseases, today announced clinical and translational findings featured in

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

Mon, 12 Oct 2026 08:05:00 -0400

Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development

Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts

Microbiome and transcriptomic analyses support the delivery platform and a potential precision medicine approach

Raymond James Starts Palisade Bio Inc. (PALI) at Outperform, PT $6

Thu, 08 Oct 2026 16:06:29 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Palisade Bio Inc. (NASDAQ: PALI) with a Outperform rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Palisade Bio (PALI) with an Outperform rating and a $6 target price. Palisade is a clinical-stage biotechnology company developing PALI-2108 — a novel once-daily oral PDE4 inhibitor prodrug — for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). We believe PALI shares present a compelling risk/reward skew ahead of Phase 2 ASCENTRA-UC/CD data updates for PALI-2108 beginning in 2027."

For

Raymond James Starts Palisade Bio Inc. (PALI) at Outperform, PT $6

Thu, 08 Oct 2026 16:06:29 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Palisade Bio Inc. (NASDAQ: PALI) with a Outperform rating and a price target of $6.00.

For

Raymond James Starts Palisade Bio Inc. (PALI) at Outperform, PT $6

Thu, 08 Oct 2026 16:06:29 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Palisade Bio Inc. (NASDAQ: PALI) with a Outperform rating and a price target of $6.00.

For

Raymond James Starts Palisade Bio Inc. (PALI) at Outperform, PT $6

Thu, 08 Oct 2026 16:06:29 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Palisade Bio Inc. (NASDAQ: PALI) with a Outperform rating and a price target of $6.00.

For

Form 4 PALISADE BIO, INC. For: Oct 06 Filed by: Jones Mitchell Lawrence

Wed, 07 Oct 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20261007/27162349.html

Form 4 PALISADE BIO, INC. For: Oct 06 Filed by: Finley John David

Wed, 07 Oct 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20261007/27162348.html

Form 4 PALISADE BIO, INC. For: Oct 01 Filed by: Williams Donald Allen

Mon, 05 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261005/27150028.html

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

Mon, 28 Sep 2026 08:50:00 -0400

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease

Three moderated posters to showcase gut-targeted exposure, favorable safety and tolerability, rapid clinical response in ulcerative colitis, and the development of a biomarker to predict treatment response

Denver, CO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that its lead program, PALI-2108, will be featured in four presentations at United

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

Mon, 28 Sep 2026 08:50:00 -0400

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease

Palisade Bio gets Health Canada nod for ulcerative colitis trial

Wed, 23 Sep 2026 08:45:17 -0400

Palisade Bio, Inc. (Nasdaq: PALI) announced that Health Canada has cleared the company's Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating the drug candidate PALI-2108 in patients with moderately to severely active ulcerative colitis.

The clearance allows Palisade Bio to begin clinical trial activities in Canada, adding to a prior regulatory clearance in the United States. The company said patient dosing is expected to begin in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.

ASCENTRA-UC is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 trial. The study is expected to enroll

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Wed, 23 Sep 2026 08:45:00 -0400

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108

Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027

Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Wed, 23 Sep 2026 08:45:00 -0400

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108

Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027

Palisade Bio gets FDA clearance for Crohn's disease drug trial

Tue, 22 Sep 2026 08:35:13 -0400

Palisade Bio, Inc. (Nasdaq: PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PALI-2108, allowing the company to initiate a Phase 2 clinical trial in patients with moderate to severe Crohn's disease.

The trial, called ASCENTRA-CD, is a multicenter, open-label, single-arm study designed to enroll approximately 60 adults. Patients will undergo a 14-day dose titration to a target dose of 30 mg orally once daily, followed by a 12-week induction phase and a 36-week maintenance phase.

The primary endpoint is endoscopic response at Week 12, defined as at least a 50% reduction from baseline

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

Tue, 22 Sep 2026 08:35:00 -0400

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease

First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028

Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity

Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

Tue, 22 Sep 2026 08:35:00 -0400

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease

First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028

Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity